ArticleObesity surgery2026
Beyond Initial Resolution: Predictors of Recurrence of Obesity-related Medical Conditions after Metabolic and Bariatric Surgery.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMetabolic and bariatric surgery (MBS) provides high rates of remission of obesity-related medical conditions (ORMC). However, recurrence of previously resolved ORMC remains an important concern. There is limited data on predictors of obesity-related medical conditions recurrence (ORMCR).
methodsA retrospective study was conducted of patients undergoing primary sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), or duodenal switch (DS) between 2008 and 2022. Patients with ≥ 36 months of follow-up, ≥ 20% total weight loss, and initial remission of type 2 diabetes mellitus (T2D), hypertension (HTN), hyperlipidemia (HLD), or obstructive sleep apnea (OSA) were included. ORMC resolution and recurrence were defined using prespecified criteria. Recurrent weight gain (RWG) was categorized as no RWG (≤ 20%), moderate RWG (> 20%-≤50%), and severe RWG (> 50%). Separate multivariable Cox regression models were constructed for each ORMCR outcome.
resultsAmong 1,323 patients with remission of at least one ORMC, ORMCR occurred in 76 (16.2%) patients with T2D, 117 (21.3%) with HTN, 71 (19.0%) with HLD, and 40 (5.4%) with OSA. Severe RWG was independently associated with increased HLD recurrence. RYGB and DS were associated with lower risks of T2D and HLD recurrence compared with SG, whereas T2D and HTN recurrence were driven by insulin dependence and higher HbA1c for T2D, and greater antihypertensive medication burden and older age for HTN. White race was protective against HTN recurrence.
conclusionsThe metabolic benefits of MBS remained largely durable, with ORMCR driven more strongly by baseline disease severity and patient-specific factors than by RWG itself.
Indexed as
Identifiers
42432395What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.